Annual Report 2002 - Roche

More documents

Recommendations

Info

Roche Securities Share price performance in CHF Roche share (adjusted) Swiss Market Index (rebased) 300 250 200 150 100 50 0 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 Non-voting equity security (Genussschein) price performance in CHF Roche non-voting equity security (adjusted) Swiss Market Index (rebased) 200 160 120 80 40 0 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 American Depositary Receipt (ADR) price performance in USD Roche ADR (adjusted) S&P 500 Index (rebased) 140 120 100 80 60 40 20 0 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 One Roche American Depositary Receipt (ADR) is equivalent to one non-voting equity security (Genussschein). ADRs have been traded in the United States over-the-counter market since July 1992. 124 Roche Securities
Number of shares and non-voting equity securities a) 1998 1999 2000 2001 2002 Number of shares (nominal value 1998–2000: CHF 100, 2001–2002: CHF 1.00) 1,600,000 1,600,000 1,600,000 160,000,000 160,000,000 Number of non-voting equity securities (Genussscheine) (no nominal value) 7,025,627 7,025,627 7,025,627 702,562,700 702,562,700 Total 8,625,627 8,625,627 8,625,627 862,562,700 862,562,700 c) in CHF Data per share and non-voting equity security Net income 509 668 1,024 4.37 (4.80) Equity 2,512 3,125 3,201 33.59 24.13 Dividend 87 100 d) 115 1.30 1.45 e) Stock price of share b) High 26,278 27,348 26,375 201.00 195.00 Low 20,633 24,210 16,800 114.00 130.50 Year-end 24,210 25,305 20,100 136.00 175.00 Stock price of non-voting High 17,112 18,760 18,755 165.35 132.75 equity security Low 13,085 15,489 14,900 95.10 92.00 (Genussschein) b) Year-end 16,245 18,319 16,510 118.50 96.35 Historic stock price (unadjusted) Shares Year-end 24,875 26,000 20,100 136.00 175.00 Non-voting equity securities (Genussschein) Year-end 16,760 18,900 16,510 118.50 96.35 in millions of CHF Market capitalisation (unadjusted) Year-end 157,550 174,384 148,153 105,014 95,692 Key ratios (year-end) Net income as % of equity 20 21 31 13 –19 Dividend yield of shares in % 0.3 0.4 0.6 1.0 0.8 Dividend yield of non-voting equity securities (Genussscheine) in % 0.5 0.5 0.7 1.1 1.5 Price/earnings of shares (unadjusted) 49 39 20 31 –36 Price/earnings of non-voting equity securities (Genussscheine) (unadjusted) 33 28 16 27 –20 Ticker symbols a) Each non-voting equity security (Genussschein) confers the same rights as any of the shares to participate in the available earnings and any remaining proceeds from liquidation following repayment of the nominal value of the shares and the participation certificate capital (if any). Shares and non-voting equity securities are listed on the Swiss Exchange. Roche Holding Ltd has no restrictions as to ownership of its shares or non-voting equity securities. b) All stock price data reflect daily closing prices. Stock price figures prior to 8 June 2000 are adjusted for the effects of the Givaudan spin-off. The adjustment factors used are 0.97325 (shares) and 0.96925 (non-voting equity securities), which are the factors used by independent financial institutions. c) The net income per share (prior to 2000) and market capitalisation figures assume that the own equity instruments held are outstanding. d) 1999 dividend does not include the special dividend relating to the spin-off of the Fragrances and Flavours Division. e) 2002 dividend as proposed by the Board of Directors. Share Non-voting American equity security Depositary Receipt Reuters ROCZ.S ROCZg.S ROHHY.PK Bloomberg RO SW ROG SW ROHHY US SWX Swiss Exchange RO ROG – Roche Securities 125
Page 1 and 2:
Annual Report 2002 Roche Group Annu
Page 3 and 4:
Group Performance at a Glance Sales
Page 5 and 6:
Roche Group Annual Report and Group
Page 7 and 8:
The sale of the Vitamins and Fine C
Page 9 and 10:
While continuing with the successfu
Page 11 and 12:
in biotechnology. At the beginning
Page 13 and 14:
emain stable. Given the volatility
Page 15 and 16:
Board of Directors as of 1 January
Page 17 and 18:
Executive Committee from 1 January
Page 19 and 20:
persons closely associated with the
Page 21 and 22:
usinesses through targeted acquisit
Page 23 and 24:
Pharmaceuticals Division in brief c
Page 25 and 26:
also posted double-digit gains. Alt
Page 27 and 28:
Western Europe. In November this no
Page 29 and 30:
Transplantation - strong growth for
Page 31 and 32:
ing positive decisions on both fili
Page 33 and 34:
Research and development - substant
Page 35 and 36:
Substantially expanded pipeline Ind
Page 37 and 38:
oncology portfolio, the roll-out of
Page 39 and 40:
Diagnostics Division in brief chang
Page 41 and 42:
Helping to shape the future. Roche
Page 43 and 44:
thing from glucose self-monitoring
Page 45 and 46:
Centralized Diagnostics. Sales by o
Page 47 and 48:
The global roll-out of Cobas TaqMan
Page 49 and 50:
Vitamins and Fine Chemicals Divisio
Page 51 and 52:
division outperformed expectations
Page 53 and 54:
People and the Environment Human re
Page 55 and 56:
worldwide the opportunity to purcha
Page 57 and 58:
Safety and Environmental Protection
Page 59 and 60:
Social Involvement The many faces o
Page 61 and 62:
‘We do not intend to make a profi
Page 63 and 64:
Financial Review Figures reported F
Page 65 and 66:
Treasury and Financing During 2002
Page 67 and 68:
Operating profit: Double-digit incr
Page 69 and 70:
Pharmaceuticals: Operating profit a
Page 71 and 72:
Net income in millions of CHF On a
Page 73 and 74:
Foreign currency translation effect
Page 75 and 76:
The adjusted basis The concept of t
Page 77 and 78:
in millions of CHF Reconciliation o
Page 79 and 80: Consolidated balance sheet in milli
Page 81 and 82: Consolidated cash flow statement in
Page 83 and 84: Foreign currency translation Most G
Page 85 and 86: Deferred income tax is provided, us
Page 87 and 88: Provisions Provisions are recognise
Page 89 and 90: Changes effective 1 January 2001 Se
Page 91 and 92: Liquidity risk Group companies need
Page 93 and 94: Total Core Vitamines and Pharmaceut
Page 95 and 96: of which the Group’s majority int
Page 97 and 98: 6. Chugai On 10 December 2001, Roch
Page 99 and 100: The fair value adjustments to inven
Page 101 and 102: Vitamin case Following the settleme
Page 103 and 104: 10. Employee benefits in millions o
Page 105 and 106: The Group operates defined benefit
Page 107 and 108: 12. Financial income (expense), net
Page 109 and 110: Income tax assets and liabilities A
Page 111 and 112: Patents, licences, trademarks 2002
Page 113 and 114: 18. Other long-term assets in milli
Page 115 and 116: 25. Equity Share capital At the Ann
Page 117 and 118: 28. Minority interests in millions
Page 119 and 120: The carrying value of the Group’s
Page 121 and 122: 2002 2001 Foreign currency derivati
Page 123 and 124: 33. Cash flow statement in millions
Page 125 and 126: Report of the Group Auditors To the
Page 127 and 128: 1995 1996 1997 c) 1998 1999 2000 20
Page 129: Additions to property, plant and eq
Page 133 and 134: Outstanding issues Summarised issue
Page 135 and 136: Balance sheet at 31 December in mil
Page 137 and 138: Participations The major participat
Page 139 and 140: Report of the Statutory Auditors To
Page 141 and 142: 120° 30° 150° 90° 60° 30° 0°
Page 143 and 144: Garden City, 70.000 GBP | Roche Reg
Page 145 and 146: Diagnostics 27% Sales by division 1
show all

Annual Report 2002 - Roche

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?